Clinical Trial

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Study acronym: EPHIC-DIA2
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated February 23, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are: * Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile? * What medical problems do participants experience while taking the treatment? Participants will: * Take the treatment described according to the Summary of Product Characteristics (SmPC). * Visit the clinic once every 12 weeks for checkups and tests. * Keep a diary of their symptoms to inform the Investigator.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-02-21; most recent amendment 2026-02-20.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-02-20
Trial Details
NCT Number NCT06851962
Lead Sponsor Fundación para la Investigación del Hospital Clínico de Valencia
Collaborators: Instituto de Salud Carlos III, European Union
Conditions Diabetes Mellitus Type 2
Enrollment 504 participants
Start Date 2025-05-26
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-23